FlandersBio on Twitter

Follow us on Twitter

collaborations - News

collaborations - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Biocartis and Merck to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing

07.01.2016

Biocartis, an innovative molecular diagnostics company, today announced that Biocartis has signed a collaboration agreement with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be developed on Biocartis' innovative, fully automated molecular diagnostics system, Idylla(TM), which is designed to offer accurate and reliable molecular information from virtually any biological sample in virtually any setting. The new test aims to support clinical practice in performing integrated liquid biopsy RAS biomarker tests, independently of the laboratories' volume of testing or level of expertise. read more

Complix Enters into Strategic Collaboration with MSD to Develop Cell-Penetrating Alphabodies to Treat Cancer

06.01.2016

Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announced it has entered into a strategic drug discovery collaboration with Merck & Co., Inc. (known as “MSD” or “Merck” (in the United States and Canada)) through its subsidiary, Merck Sharp & Dohme Corp., to develop Cell-Penetrating Alphabodies (CPABs) for the treatment of cancer. read more

HistoGeneX kiest Quality by Design voor kwaliteitsbewaking

14.12.2015

HistoGeneX schakelt de hulp in van Quality by Design (QbD), de expert in kwaliteitsbewaking voor bedrijven in de farmaceutische, biotechnologische en cosmeticasector. Door de snelle, forse groei van HistoGeneX – gespecialiseerd in het ontwikkelen van predictieve biomarkers voor kankerbehandelingen – moest de organisatie op zoek naar een partner voor de constante validatie van zijn computersystemen. De keuze viel op QbD vanwege de track record die de onderneming heeft opgebouwd bij andere bedrijven in de sector. Met de samenwerking optimaliseert HistoGeneX zijn IT-procedures en computersystemen. Zo is het bedrijf in staat de veiligheid van patiëntgegevens te garanderen en bij een audit of overheidsinspectie aan te tonen dat de integriteit van zijn data gewaarborgd is. read more

Complix Advances Novel Biospecific Immunotherapeutic CMX-02 - Enters Agreement with Selexis

14.12.2015

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease. CMX-02 is a bispecific Alphabody-antibody fusion protein that simultaneously targets TNFα and IL-23. The Company has entered into an agreement with Switzerland-based Selexis SA to enable the production of this novel drug candidate. read more

MDxHealth Announces ConfirmMDx Marketing Partnership in Central/South America

08.12.2015

MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with SouthGenetics Inc. for the commercialization of its ConfirmMDx® for Prostate Cancer test in twelve countries across Central and South America. read more

ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK

25.11.2015

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody® drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody programme. read more

Ovizio partners with Pall Life Sciences to expand and commercialize the iLine S microscope range

29.10.2015

Ovizio Imaging Systems, an innovative microscopy company specializing in automated cell culture monitoring systems, and Pall Life Sciences, a global leader in biopharmaceutical fluid management, today announce the signing of a long term global supply agreement for the iLine S microscope. The financial terms of the agreement have not been disclosed. read more

UGent, UZ Gent en Janssen Pharmaceutica bouwen wetenschappelijke samenwerking uit

29.10.2015

De UGent, UZ Gent en Janssen Pharmaceutica gaan nauwer samenwerken op het vlak van innovatief onderzoek, om zo beter in te spelen op maatschappelijke en economische uitdagingen en medische innovaties sneller tot bij de patiënt te brengen. read more

ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.

15.10.2015

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has achieved pre-clinical proof-of-concept with a Nanobody construct as part of its immuno-oncology collaboration with Merck & Co., Inc. ("Merck") [known as MSD outside the United States and Canada], triggering a €3.5 million milestone payment to Ablynx. This collaboration with Merck includes the discovery and development of up to 17 Nanobody programmes against individual protein targets and target combinations (mono-specific and multi-specific Nanobodies) for application in immuno-oncology indications. read more

Sengenics and Diploid Sign Exclusive Agreement to Streamline Clinical Exome Sequencing in the Middle East

18.09.2015

Sengenics today announced an exclusive partnership with Diploid, a Belgium-based Human Genome Interpretation service provider to enable more streamlined Clinical Exome and Genome sequencing in the Middle East and GCC countries. Key areas of collaboration include clinical exome and whole genome sequencing, cross-leveraging proprietary mutation databases and clinical interpretation by a panel of clinical geneticists. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print